 Sunita Sharma
Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 34 | 2024 | 2225 | 5.590 |
Why?
| | Gastroesophageal Reflux | 2 | 2023 | 232 | 1.300 |
Why?
| | Lung | 16 | 2024 | 3938 | 1.120 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2022 | 984 | 1.080 |
Why?
| | Adrenal Cortex Hormones | 3 | 2021 | 524 | 0.980 |
Why?
| | Adrenergic beta-Agonists | 2 | 2020 | 133 | 0.950 |
Why?
| | Genome-Wide Association Study | 8 | 2023 | 1326 | 0.920 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2024 | 646 | 0.810 |
Why?
| | DNA Methylation | 5 | 2024 | 611 | 0.710 |
Why?
| | Gene Expression Regulation | 3 | 2022 | 2542 | 0.700 |
Why?
| | Smoke | 2 | 2023 | 140 | 0.700 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2022 | 275 | 0.690 |
Why?
| | Dermatitis, Atopic | 2 | 2024 | 319 | 0.670 |
Why?
| | Dyspnea | 1 | 2022 | 239 | 0.660 |
Why?
| | GTP Phosphohydrolases | 1 | 2020 | 86 | 0.660 |
Why?
| | Gene Expression Profiling | 6 | 2016 | 1687 | 0.650 |
Why?
| | MicroRNAs | 3 | 2024 | 679 | 0.630 |
Why?
| | Epigenesis, Genetic | 3 | 2023 | 617 | 0.630 |
Why?
| | Genomics | 3 | 2020 | 718 | 0.610 |
Why?
| | Exercise Test | 1 | 2022 | 613 | 0.610 |
Why?
| | Marijuana Use | 1 | 2022 | 192 | 0.600 |
Why?
| | Glucocorticoids | 2 | 2020 | 580 | 0.600 |
Why?
| | Genetic Predisposition to Disease | 9 | 2023 | 2274 | 0.560 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2018 | 101 | 0.550 |
Why?
| | Dietary Supplements | 3 | 2019 | 534 | 0.550 |
Why?
| | Ascorbic Acid | 1 | 2017 | 120 | 0.530 |
Why?
| | Polymorphism, Single Nucleotide | 8 | 2023 | 2060 | 0.500 |
Why?
| | Gene Expression Regulation, Developmental | 4 | 2016 | 824 | 0.490 |
Why?
| | Humans | 48 | 2024 | 129625 | 0.490 |
Why?
| | Quantitative Trait Loci | 1 | 2017 | 353 | 0.480 |
Why?
| | Phenotype | 6 | 2024 | 3075 | 0.470 |
Why?
| | Cannabis | 1 | 2022 | 462 | 0.470 |
Why?
| | Pulmonary Emphysema | 1 | 2017 | 275 | 0.460 |
Why?
| | alpha-N-Acetylgalactosaminidase | 1 | 2014 | 2 | 0.460 |
Why?
| | Genes, Developmental | 1 | 2014 | 2 | 0.450 |
Why?
| | Fatty Acid Desaturases | 1 | 2014 | 32 | 0.440 |
Why?
| | Biomarkers | 3 | 2022 | 3968 | 0.430 |
Why?
| | Vitamin B Complex | 1 | 2013 | 41 | 0.420 |
Why?
| | Dexamethasone | 1 | 2015 | 350 | 0.400 |
Why?
| | Environmental Exposure | 3 | 2014 | 463 | 0.400 |
Why?
| | Food | 1 | 2013 | 156 | 0.390 |
Why?
| | Citrulline | 2 | 2023 | 43 | 0.360 |
Why?
| | Epidemiologic Studies | 1 | 2011 | 64 | 0.350 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2014 | 1058 | 0.340 |
Why?
| | Bronchodilator Agents | 2 | 2023 | 241 | 0.320 |
Why?
| | Pyroglyphidae | 1 | 2008 | 19 | 0.310 |
Why?
| | Wnt Proteins | 1 | 2009 | 127 | 0.310 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2008 | 158 | 0.290 |
Why?
| | Obesity | 4 | 2022 | 2882 | 0.280 |
Why?
| | Placenta | 3 | 2023 | 723 | 0.270 |
Why?
| | Case-Control Studies | 5 | 2024 | 3378 | 0.250 |
Why?
| | Lung Diseases | 2 | 2016 | 741 | 0.230 |
Why?
| | Child | 12 | 2023 | 20884 | 0.230 |
Why?
| | Principal Component Analysis | 3 | 2016 | 190 | 0.230 |
Why?
| | Respiratory Function Tests | 2 | 2020 | 581 | 0.230 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 277 | 0.220 |
Why?
| | Administration, Inhalation | 2 | 2020 | 667 | 0.220 |
Why?
| | Double-Blind Method | 4 | 2016 | 1875 | 0.210 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2024 | 83 | 0.210 |
Why?
| | Congresses as Topic | 1 | 2024 | 216 | 0.200 |
Why?
| | Mendelian Randomization Analysis | 1 | 2023 | 47 | 0.200 |
Why?
| | Risk Factors | 7 | 2022 | 9786 | 0.200 |
Why?
| | Causality | 1 | 2023 | 117 | 0.200 |
Why?
| | Male | 21 | 2024 | 63670 | 0.200 |
Why?
| | Aryldialkylphosphatase | 1 | 2022 | 18 | 0.190 |
Why?
| | Female | 22 | 2024 | 68734 | 0.190 |
Why?
| | Immunity | 1 | 2022 | 138 | 0.180 |
Why?
| | Hospitalization | 2 | 2020 | 2057 | 0.180 |
Why?
| | Marijuana Smoking | 1 | 2024 | 247 | 0.180 |
Why?
| | Symptom Flare Up | 1 | 2020 | 38 | 0.180 |
Why?
| | RNA, Messenger | 3 | 2024 | 2708 | 0.170 |
Why?
| | Forced Expiratory Volume | 4 | 2019 | 506 | 0.170 |
Why?
| | GTPase-Activating Proteins | 1 | 2020 | 81 | 0.170 |
Why?
| | Chemotaxis | 1 | 2020 | 129 | 0.170 |
Why?
| | Genetic Loci | 2 | 2023 | 275 | 0.170 |
Why?
| | Fetus | 2 | 2016 | 774 | 0.170 |
Why?
| | Severity of Illness Index | 3 | 2020 | 2739 | 0.170 |
Why?
| | Smoking | 2 | 2020 | 1500 | 0.160 |
Why?
| | Exercise Tolerance | 1 | 2022 | 273 | 0.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 757 | 0.150 |
Why?
| | Interleukins | 1 | 2020 | 241 | 0.150 |
Why?
| | Nedocromil | 2 | 2008 | 32 | 0.150 |
Why?
| | Treatment Outcome | 4 | 2020 | 10219 | 0.150 |
Why?
| | Particulate Matter | 1 | 2020 | 247 | 0.150 |
Why?
| | Administration, Oral | 1 | 2021 | 787 | 0.150 |
Why?
| | Maternal Exposure | 2 | 2017 | 177 | 0.150 |
Why?
| | Guidelines as Topic | 1 | 2020 | 264 | 0.150 |
Why?
| | Vital Capacity | 2 | 2009 | 289 | 0.150 |
Why?
| | Air Pollution | 1 | 2020 | 218 | 0.140 |
Why?
| | Databases, Genetic | 2 | 2016 | 230 | 0.140 |
Why?
| | Child, Preschool | 4 | 2023 | 10490 | 0.140 |
Why?
| | Pregnancy | 5 | 2023 | 6417 | 0.140 |
Why?
| | Histones | 1 | 2022 | 589 | 0.130 |
Why?
| | Quality of Life | 3 | 2023 | 2688 | 0.130 |
Why?
| | Comorbidity | 1 | 2021 | 1547 | 0.130 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1432 | 0.130 |
Why?
| | Vitamins | 1 | 2017 | 173 | 0.130 |
Why?
| | Folic Acid | 1 | 2017 | 184 | 0.130 |
Why?
| | Arginine | 3 | 2023 | 263 | 0.130 |
Why?
| | Betamethasone | 1 | 2015 | 20 | 0.120 |
Why?
| | CCAAT-Enhancer-Binding Protein-delta | 1 | 2015 | 5 | 0.120 |
Why?
| | Cadherins | 1 | 2017 | 190 | 0.120 |
Why?
| | Animals | 7 | 2018 | 35391 | 0.120 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2015 | 27 | 0.120 |
Why?
| | Animals, Newborn | 2 | 2015 | 835 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2016 | 756 | 0.120 |
Why?
| | Neutrophils | 1 | 2020 | 1210 | 0.120 |
Why?
| | Costa Rica | 1 | 2014 | 16 | 0.110 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2015 | 103 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2020 | 855 | 0.110 |
Why?
| | Nitric Oxide | 1 | 2019 | 895 | 0.110 |
Why?
| | Genetic Markers | 1 | 2015 | 336 | 0.110 |
Why?
| | Prevalence | 1 | 2020 | 2564 | 0.110 |
Why?
| | Gestational Age | 3 | 2012 | 876 | 0.100 |
Why?
| | Ornithine | 2 | 2023 | 25 | 0.100 |
Why?
| | Cohort Studies | 4 | 2017 | 5426 | 0.100 |
Why?
| | Gene Expression | 1 | 2018 | 1465 | 0.100 |
Why?
| | Epigenomics | 2 | 2023 | 110 | 0.100 |
Why?
| | Cotinine | 1 | 2012 | 75 | 0.100 |
Why?
| | Maternal Behavior | 1 | 2012 | 74 | 0.100 |
Why?
| | Acetyl-CoA C-Acyltransferase | 1 | 2011 | 1 | 0.100 |
Why?
| | Nicotine | 1 | 2014 | 302 | 0.100 |
Why?
| | Premature Birth | 1 | 2015 | 317 | 0.090 |
Why?
| | Morbidity | 2 | 2023 | 302 | 0.090 |
Why?
| | Sex Characteristics | 1 | 2016 | 736 | 0.090 |
Why?
| | Alleles | 2 | 2017 | 847 | 0.090 |
Why?
| | Adult | 9 | 2024 | 35599 | 0.090 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 574 | 0.090 |
Why?
| | Endotoxins | 1 | 2011 | 220 | 0.090 |
Why?
| | Intestines | 1 | 2013 | 347 | 0.090 |
Why?
| | Vitamin D | 1 | 2013 | 381 | 0.080 |
Why?
| | Transcriptome | 1 | 2016 | 876 | 0.080 |
Why?
| | Adolescent | 4 | 2024 | 20412 | 0.080 |
Why?
| | Signal Transduction | 2 | 2020 | 4931 | 0.080 |
Why?
| | Mice, Inbred C57BL | 3 | 2015 | 5455 | 0.080 |
Why?
| | Computational Biology | 1 | 2013 | 596 | 0.080 |
Why?
| | Infant, Newborn | 2 | 2017 | 5756 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2021 | 2342 | 0.080 |
Why?
| | Prospective Studies | 4 | 2024 | 7135 | 0.080 |
Why?
| | Budesonide | 1 | 2008 | 89 | 0.070 |
Why?
| | Bronchial Hyperreactivity | 1 | 2008 | 109 | 0.070 |
Why?
| | Spirometry | 1 | 2008 | 255 | 0.070 |
Why?
| | Genetic Association Studies | 1 | 2009 | 362 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1499 | 0.070 |
Why?
| | Transcription Factors | 1 | 2015 | 1647 | 0.070 |
Why?
| | Inflammation | 1 | 2018 | 2750 | 0.070 |
Why?
| | Middle Aged | 6 | 2024 | 31136 | 0.070 |
Why?
| | United States | 2 | 2021 | 13871 | 0.060 |
Why?
| | Microbiota | 1 | 2013 | 733 | 0.060 |
Why?
| | Allergens | 1 | 2008 | 385 | 0.060 |
Why?
| | Autopsy | 1 | 2005 | 90 | 0.060 |
Why?
| | Mice | 4 | 2015 | 16961 | 0.060 |
Why?
| | Anti-Asthmatic Agents | 1 | 2008 | 374 | 0.060 |
Why?
| | Dietary Sugars | 1 | 2024 | 13 | 0.060 |
Why?
| | Oxidative Stress | 2 | 2022 | 1266 | 0.060 |
Why?
| | Interleukin-5 | 1 | 2024 | 45 | 0.060 |
Why?
| | Young Adult | 4 | 2024 | 12455 | 0.050 |
Why?
| | Albuterol | 1 | 2023 | 105 | 0.050 |
Why?
| | Quercetin | 1 | 2022 | 10 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2023 | 129 | 0.050 |
Why?
| | Fibroblast Growth Factors | 1 | 2023 | 169 | 0.050 |
Why?
| | Aged | 4 | 2024 | 22061 | 0.050 |
Why?
| | Hydrogen Peroxide | 1 | 2022 | 317 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2024 | 602 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2019 | 69 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2008 | 4894 | 0.040 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2019 | 171 | 0.040 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 242 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2021 | 370 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2023 | 1075 | 0.030 |
Why?
| | Netherlands | 1 | 2016 | 77 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2627 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2020 | 613 | 0.030 |
Why?
| | Demography | 1 | 2017 | 279 | 0.030 |
Why?
| | Vaccination | 1 | 2024 | 1347 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 735 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 1986 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 305 | 0.030 |
Why?
| | Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2014 | 6 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 1592 | 0.030 |
Why?
| | CpG Islands | 1 | 2014 | 152 | 0.030 |
Why?
| | Cytochrome P-450 CYP1B1 | 1 | 2012 | 5 | 0.030 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2012 | 9 | 0.030 |
Why?
| | Exercise | 1 | 2024 | 1928 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2012 | 90 | 0.030 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 48 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2274 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 5415 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5075 | 0.020 |
Why?
| | Eczema | 1 | 2011 | 67 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2011 | 257 | 0.020 |
Why?
| | ROC Curve | 1 | 2012 | 503 | 0.020 |
Why?
| | Models, Animal | 1 | 2012 | 378 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 949 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 502 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 2011 | 330 | 0.020 |
Why?
| | Up-Regulation | 1 | 2012 | 840 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2016 | 2720 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 7052 | 0.020 |
Why?
| | Linear Models | 1 | 2011 | 819 | 0.020 |
Why?
| | Age Factors | 1 | 2016 | 3152 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 1019 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2011 | 877 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2005 | 14522 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1843 | 0.020 |
Why?
| | Cell Line | 1 | 2013 | 2784 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 1947 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1833 | 0.020 |
Why?
| | Liver | 1 | 2012 | 1842 | 0.010 |
Why?
| | Risk Assessment | 1 | 2011 | 3262 | 0.010 |
Why?
| | Infant | 1 | 2011 | 8995 | 0.010 |
Why?
|
|
Sharma's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|